The association of steroid 5-alpha reductase type-II gene polymorphisms (A49T and V89L) with prostate cancer risk in African population: A systematic review and meta-analysis
Authors:
Open Access
- 15 September 2024
- journal article
- review article
- Published by Elsevier in Scientific African
- Vol. 26
Abstract
No abstract availableKeywords
Funding Information
- Covenant University
This publication has 44 references indexed in Scilit:
- Androgens in prostate cancer: A tale that never endsCancer Letters, 2021
- Androgen Signaling in the Tumor Microenvironment2020
- The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A reviewAsian Journal of Urology, 2020
- Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysisMolecular Biology Reports, 2013
- International Variation in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2012
- Cancer burden in Africa and opportunities for preventionCancer, 2012
- Genetic Defects of Androgen Resistance2010
- Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian populationCancer Genetics and Cytogenetics, 2009
- SRD5A2andHSD3B2polymorphisms are associated with prostate cancer risk and aggressivenessThe Prostate, 2007
- Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the ARThe Prostate, 2003